Henghui Cheng

Prof. Dr. Henghui Cheng


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
XSXuhui Sun
Xuhui Sun
WJWenlong Jia
Wenlong Jia
HLHuifang Liang
Huifang Liang
HCHenghui Cheng
Henghui Cheng
Background: Immunotherapy has emerged as a pivotal therapeutic modality for a multitude of malignancies, notably hepatocellular carcinoma (HCC). This research endeavors to construct a prognostic signature based on immune-related genes between different HCC molecular subtypes, offer guidance for immunotherapy application, and promote its clinical practical application through immunohistochemistry.Methods: Distinguishing HCC subtypes through Gene set variation analysis and Consensus clustering analysis using the Kyoto Encyclopedia of Genes and Genome (KEGG) pathway. In the TCGA-LIHC cohort, univariate, Lasso, and multivariate Cox regression analyses were applied to construct a novel immune relevant prognostic signature. The Subtype-specific and Immune-Related Prognostic Signatures (SIR-PS) were validated in three prognostic cohorts, one immunotherapy cohort, different HCC cell lines and tissue chips. Further possible mechanism on immunotherapy was explored by miRNA-mRNA interactions and signaling pathway.Results: This prognostic model, which was based on four critical immune-related genes, STC2, BIRC5, EPO and GLP1R, was demonstrated excellent performance in both prognosis and immune response prediction of HCC. Clinical pathological signature, tumor microenvironment and mutation analysis also proved the effective prediction of this model. Spatial transcriptome analysis shows that STC2 and BIRC5 are mainly enriched in liver cancer cells and their mRNA and protein expression levels were greater in higher malignant HCC cell lines than in the lower ones. Further validation on HCC tissue chips of this model also showed good correlation with cancer prognosis. The risk score of each patient demonstrated that the SIR-PS exhibited excellent 1 and 3-year survival prediction performance.Conclusions: Our analysis demonstrates that the SIR-PS model serves as a robust prognostic and predictive tool for both the survival outcomes and the response to immunotherapy in hepatocellular carcinoma patients, which may shed light on promoting the individualized immunotherapy against hepatocellular carcinoma.

15 September 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
YDYuhong Dai
Yuhong Dai
YLYongqing Liu
Yongqing Liu
ZGZhimin Gong
Zhimin Gong
LHLilin He
Lilin He
LWLei Wang
Lei Wang
HQHong Qiu
Hong Qiu
Background: Immune-checkpoint inhibitors (ICIs) combined with chemotherapy have been successfully used in clinical trials to treat advanced gastric cancer. However, the efficacy and safety of first-line immunotherapy combined with chemotherapy in Chinese patients are unknown.Methods: This multicenter retrospective study included patients with human epidermal growth factor receptor-2 (HER-2) negative advanced gastric cancer treated with first-line chemotherapy or chemotherapy with an ICI between January 2019 and December 2022. Propensity score matching was used to compare progression-free survival (PFS), overall survival, objective response rates, and adverse reactions between cohorts.Results: After propensity score matching, 138 patients, who had balanced baseline characteristics, were included in the chemotherapy and combination treatment groups. The median follow-up duration was 16.90 months, and the median PFS was 8.53 months (95% confidence interval [CI] 7.77-9.28) in the combination treatment group and 5.97 months (95% CI 4.56-7.37) in the chemotherapy group. The median survival duration was 17.05 months (95% CI 14.18-19.92) in the combination treatment group and 16.46 months (95% CI 12.99-19.93) in the chemotherapy group. The PFS subgroup analysis revealed that age ≥65 years, women, Eastern Cooperative Oncology Group performance status of 1, non-signet ring cell carcinoma, esophagogastric junction, liver metastasis, peritoneal metastasis, no massive ascites, only one metastatic organ, and combined platinum-based chemotherapy correlated with treatment benefit. The incidences of adverse events above grade 3 were comparable between groups.Conclusions: Our study confirmed the ATTRACTION-4 trial results. Compared with chemotherapy, first-line ICIs combined with chemotherapy prolonged PFS but did not improve overall survival in patients with HER-2-negative advanced gastric cancer.

30 December 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
HCHenghui Cheng
Henghui Cheng
JWJie Wu
Jie Wu
HPHui Peng
Hui Peng
JLJiangyuan Li
Jiangyuan Li
ZLZhi-Min Liu
Zhi-Min Liu
LXLinglin Xie
Linglin Xie
Background/Objectives: This study builds on previous findings from mouse models, which showed that maternal overnutrition induced by a high-fat diet (HFD) promotes metabolic-associated fatty liver disease (MAFLD) in offspring, linked to global DNA hypermethylation. We explored whether epigenetic modulation with 5-Aza-CdR, a DNA methylation inhibitor, could prevent MAFLD in offspring exposed to maternal overnutrition. Methods: The offspring mice from dams of maternal overnutrition were fed either a chow diet or a high-fat diet (HFD) for 10 weeks. These mice were randomly divided into two groups: HFD, and AZA + HFD. Mice assigned to the AZA group were given 5-Aza-CdR during the last three weeks. Results: Our findings show that 5-Aza-CdR treatment in HFD-fed offspring effectively countered weight gain, improved glucose regulation, and minimized hepatic fat buildup along with serum lipid imbalances. Additionally, it boosted AMPK signaling and raised PPAR-α expression, pointing to enhanced fatty acid oxidation. We also detected an increase in JNK signaling, affecting the gene expression associated with cell death and proliferation. Notably, treated mice displayed more hepatic inflammation than the HFD group alone, suggesting a complex, dual impact on MAFLD management. Significant apoptotic and inflammatory gene changes were identified, along with corresponding differentially methylated regions triggered by 5-Aza-CdR, marking potential therapeutic targets. Conclusions: 5-Aza-CdR was shown to mitigate MAFLD features in offspring of maternal overnutrition by reversing DNA hypermethylation and improving metabolic pathways, though its dual impact on inflammation highlights the need for further research to optimize its therapeutic potential.

16 August 2025 in BMC Cancer
Verified
Journal Article
Open access
XYXiao Yang
Xiao Yang
YDYu-Hong Dai
Yu-Hong Dai
HPHui Peng
Hui Peng
MZMing-Sheng Zhang
Ming-Sheng Zhang
QFQiang Fu
Qiang Fu
LZLiang Zhuang
Liang Zhuang
The efficacy and safety of conventional first-line chemotherapeutic regimens for the treatment of advanced biliary tract carcinomas (ABTCs) have been unsatisfactory. We aimed to explore alternative chemotherapeutic regimens capable of providing improved efficacy and fewer side-effects. Multicentre, randomised, phase II clinical trial. Patients with unresectable advanced-stage tumors, or those who have developed recurrence or metastasis following initial radical surgery, between January 2021 and November 2022 were included. The participants were randomised to either a gemcitabine-cisplatin group (GC) or an albumin-paclitaxel-cisplatin group (NC). Progression-free survival (PFS) was the primary outcome, whereas overall survival (OS), and objective response rate (ORR) were the secondary outcomes. The trial enrolled 75 patients and had a median follow-up period of 11 months. The median PFS (mPFS) was 7.8 m (95% confidence interval [CI]: 5.4-14.0 m) in the NC group, and 7.0 m (95%CI: 3.9-10.1 m) in the GC group (p = 0.0034, hazard ratio [HR] = 0.5136, 95%CI: 0.3136-0.8411). Median OS for the NC group was 12.4 m (95%CI: 7.3-22.3 m) and for the GC group was 12.1 m (95%CI: 6.7-20.7 m), with no significant differences (p = 0.4592, HR = 0.811, 95%CI: 0.463-1.442). PFS rates at 6 and 8 months were 52.6% vs. 73.0% and 13.2% vs. 35.1% for the NC and the GC group, respectively (p < 0.05). As the secondary endpoint, ORR rates, there was no significant difference between the two groups. GC group had 13 (34.2%) patients achieved ORR, while NC group had 14 (37.8%). Regarding safety, In the context of thrombocytopenia, the incidence was significantly lower in the NC group compared to the GC group (27% vs 50%, P = 0.041). Conversely, with regard to sensory neuropathy, the NC group demonstrated a higher incidence (62.1% vs 36.8%, P = 0.028). In this phase II non-inferiority trial, NC demonstrated comparable efficacy to GC in advanced BTC, with a trend toward improved PFS and a potentially favorable hematological toxicity profile. Further studies are warranted to confirm these findings in the context of a modern immunotherapy-based standard. Clinical Trials.gov identifiers: NCT04692051. Registered October 31, 2018. https://www.chictr.org.cn/showproj.html?proj=38440 .

13 March 2026 in Cells
Verified
Journal Article
Open access
PDF file
XLXiaoxiao Luo
Xiaoxiao Luo
MFMin Fu
Min Fu
BZBen Zhao
Ben Zhao
FYFeng Yang
Feng Yang
YLYi-Zhou Liu
Yi-Zhou Liu
QLQian Xia Li
Qian Xia Li
Glioblastoma (GBM) is a highly aggressive brain tumor with a complex tumor microenvironment (TME) that includes immune cell infiltration, notably macrophages. The role of macrophages in GBM progression is influenced by their polarization state, which can be either pro-inflammatory (M1) or immunosuppressive (M2). This study investigates the macrophage polarization in GBM, identifying key macrophage-related genes and their impact on tumor progression. Analysis of TCGA-GBM data revealed that macrophage infiltration correlates with poor prognosis, with 41 risk-associated genes identified. DSP dataset analysis highlighted 378 differentially expressed genes between CD68+ macrophages and GFAP+ controls, including immune-related genes like SPP1, CD74, and C3. Cross-validation with single-cell RNA-seq confirmed the expression of 9 key genes, with 7 genes being macrophage-specific. In vitro experiments using conditioned media from GBM cell lines demonstrated that GBM cells promote macrophage polarization towards an M2-like phenotype. Overexpression of CD74, CLEC7A, and IFI30 in macrophages further enhanced M2 polarization, which was associated with increased tumor-promoting functions, including enhanced invasion and reduced apoptosis in GBM cells. Together, these findings highlight the role of M2 macrophage polarization in promoting GBM progression and suggest that targeting macrophage polarization pathways may offer therapeutic potential.

12 June 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MHMengzhen Han
Mengzhen Han
YPYonglong Pan
Yonglong Pan
XLXinxin Li
Xinxin Li
QHQibo Huang
Qibo Huang
HZHe Zhu
He Zhu
XLXin Luo
Xin Luo
Intrahepatic cholangiocarcinoma (iCCA), the second most common subtype of primary liver cancer around the world, is an aggressive neoplasm with high metastastic potential, which leads to a low rate of curative resections and dismal prognosis. In previous studies, Sulfatase 2 (SULF2) has been reported to regulate various important oncogenic signaling pathways and promote iCCA progression. Further research is needed to explore the role of SULF2 in iCCA metastasis. In this study, we verified the overexpression of SULF2 in iCCA tissues and its positive correlation with advanced stage and poor prognosis. Trans-well migration and invasion assay and mouse models explored the impact of SULF2 on iCCA metastasis in vitro and in vivo. We also demonstrated that SULF2 facilitated iCCA metastasis through upregulating CXCR4 transcription mediated by the transcription factor YBX1. Moreover, SULF2 could recruit USP7 to interact with YBX1 and inhibit Lys48-polyubiquitination of YBX1, stabilizing YBX1 and promoting a functional YBX1/CXCR4 axis. Combining SULF2 monoclonal antibody with SU056 had a synergistic effect in suppressing iCCA progression and metastasis of mouse models. In conclusion, SULF2 promotes iCCA progression and metastasis through an intracellular SULF2-YBX1-CXCR4 axis, and SULF2 monoclonal antibody combined with YBX1 inhibitor SU056 may be a potentially promising treatment strategy for iCCA.